目的 探討復(fù)方血栓通膠囊聯(lián)合康柏西普治療老年黃斑變性的臨床療效。方法 選取2016年1月—2020年12月河南大學第一附屬醫(yī)院收治的200例黃斑變性患者，按照隨機抽樣法將所有患者分為對照組與治療組，每組各100例。對照組患者使用康柏西普眼用注射液。治療組在注射康柏西普眼用注射液后第2天口服復(fù)方血栓通膠囊，3粒/次，3次/d，連續(xù)用藥3個月。兩組患者康柏西普注射每月1次，連續(xù)3次，并進行每月定期隨訪1次。觀察兩組的臨床療效，比較兩組眼血液動力學指標和血清相關(guān)因子水平的變化情況。結(jié)果 治療后，治療組總有效率是90.0%，顯著高于對照組的78.0%（P<0.05）。治療后，兩組收縮期峰值流速（PSV）、舒張末期流速（EDV）顯著升高，但阻力指數(shù)（RI）、黃斑中心視網(wǎng)膜厚度（CMT）顯著降低（P<0.05）；治療后，治療組眼底血流動力學指標改善優(yōu)于對照組（P<0.05）。治療后，兩組血清C-反應(yīng)蛋白（CRP）和血管內(nèi)皮生長因子（VEGF）水平顯著降低（P<0.05）；治療后，治療組血清CRP、VEGF水平低于對照組（P<0.05）。結(jié)論 復(fù)方血栓通膠囊聯(lián)合康柏西普治療老年黃斑變性具有較為理想的療效，可有效改善血清CRP、VEGF水平及眼底血流動力學指標，具有較高的臨床應(yīng)用價值。

Objective To investigate the effect of Compound Xueshuantong Capsules combined with conbercept in treatment of age-related macular degeneration. Methods A total of 200 patients with macular degeneration admitted to the First Affiliated Hospital of Henan University from January 2016 to December 2020 were selected and divided into control group and treatment group according to random sampling method, with 100 cases in each group. Patients in the control group were received Conbercept Ophthalmic Injection. Patients in the treatment group were po administered with Compound Xueshuantong Capsules on the second day after injection of Conbercept Ophthalmic Injection, three grains/time, three times daily, the drug was administered continuously for 3 months. Patients in both groups were injected with compaxerib once a month for 3 consecutive times. The clinical efficacies of two groups were observed, and the changes of ocular hemodynamic indexes and serum factor levels were compared between the two groups. Results After treatment, the total effective rate of treatment group was 90.0%, significantly higher than 78.0% of control group (P<0.05). After treatment, peak systolic flow rate (PSV) and end diastolic flow rate (EDV) were significantly increased, but resistance index (RI) and central macular retinal thickness (CMT) were significantly decreased in both groups (P<0.05). After treatment, the improvement of fundus hemodynamic indexes in the treatment group was better than that in the control group (P<0.05). After treatment, the levels of serum C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) in two groups were significantly decreased (P<0.05). After treatment, serum CRP and VEGF levels in the treatment group were lower than those in the control group (P<0.05). Conclusion Compound Xueshuantong Capsules combined with conbercept has a relatively ideal therapeutic effect in treatment of age-related macular degeneration, and can effectively improve the levels of serum CRP, VEGF and fundus hemodynamics, which has a high clinical application value.

R988.1

河南省科技計劃項目（LHGJ20190520）